CAMP and lip and oral cavity carcinoma: For instance, 5-azacytidine, a well-known DNMT inhibitor, increased CAMP and DEFB concentrations in gingival epithelial cells [111], oral carcinoma cells [127,128], keratinocytes [113], and chondrocytes [129].